Cargando…
Response to rituximab in children and adults with immune thrombocytopenia (ITP)
BACKGROUND: Rituximab is a monoclonal anti‐CD20 antibody used as a second‐line treatment for immune thrombocytopenia (ITP). As additional treatments for ITP emerge, identifying the most appropriate patients and optimal timing for rituximab are important but challenging without established predictors...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385184/ https://www.ncbi.nlm.nih.gov/pubmed/34466770 http://dx.doi.org/10.1002/rth2.12587 |